← Eichor
Study identifier: NCT06698510 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study

Condition: Schistosomiasis  ·  Sponsor: Peter Steinmann

PhaseN/A
Planned participants18500
Who can joinAll sexes, 24 Months to 59 Months
Healthy volunteersYes

About this study

The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ). The aim of the small-scale pilot study is to assess the performance of different platforms for distributing arPZQ, a child-friendly formulation of praziquantel, to the target population (i.e., preschool-aged children (PSAC)) currently missed out in schistosomiasis treatment campaigns. The specific objectives of the pilot study are: * To assess the performance of different platforms for delivery of arPZQ to PSAC aged 24 to 59 months in terms of coverage, feasibility and acceptability * To determine social mobilization and training needs for effective delivery of arPZQ through different platforms Preventive chemotherapy with arPZQ will be offered systematically to eligible PSAC aged 2 to below 5 years of consenting caregivers resident in the study area and reached through the selected platforms. Adverse events during MDA with arPZQ will be documented and reported by using existing tools and established reporting pathways aligned with standard pharmacovigilance and safety guidelines of the national drug authorities. Based on routine program processes and forms, variables pertaining to drug logistics, training,…

This description comes directly from the study's public registry record.

Talk to the study team

Peter Steinmann, PhD PD  ·  +41 61 284 82 18  ·  peter.steinmann@swisstph.ch

Nora Monnier, Dr. med.  ·  +41 61 284 82 29  ·  nora.monnier@swisstph.ch

Always discuss trial participation with your own doctor first.

Locations (7)

Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU)Abidjan, Côte d’IvoireRecruiting
Université Félix Hophouët-Boigny (UFHB), Département de sociologieAbidjan, Côte d’IvoireRecruiting
Université Félix Hophouët-Boigny (UFHB), UFR BiosciencesAbidjan, Côte d’IvoireRecruiting
African Institute for Health and Development (AIHD)Nairobi, KenyaNot Yet Recruiting
Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)Nairobi, KenyaNot Yet Recruiting
Makerere University, Department of Sociology and AnthropologyKampala, UgandaNot Yet Recruiting
Vector Borne & Neglected Tropical Disease Control Division, Ministry of HealthKampala, UgandaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06698510